Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Interleukin-12||Ro 24-7472|NM-IL-12|Edodekin alfa||Interleukin-12 (NM-IL-12) is a recombinant version of Interleukin-12 (IL-12), which may decrease tumor angiogenesis (NCI Drug Dictionary).|
|LN-145||LN145||LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary).|
|Mesna||Mesnex||D-7093|UCB 398|MSA|mercaptoethane sulfonate|Mesnum|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03449108||Phase II||Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna||Iovance Alliance: LN-145 Across Multiple Tumor Types||Recruiting||USA||0|